NCT05338294 The Effect of Laparoscopic Splenectomy and Azygoportal Disconnection on the Immune Function for Cirrhosis Patients
| NCT ID | NCT05338294 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northern Jiangsu People's Hospital |
| Condition | Cirrhosis, Liver |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2022-03-01 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2022-03-01 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, the investigators compared the improvement of immune function related indicators in patients with liver cirrhosis after laparoscopic splenectomy and azygoportal disconnection. To determine whether surgical treatment can help enhance postoperative immune function and improve patient prognosis.
Eligibility Criteria
Inclusion Criteria: * A clinical, radiological or histologic diagnosis of cirrhosis of any etiology * Splenomegaly with secondary hypersplenism * gastroesophageal variceal bleeding * Informed consent to participate in the study Exclusion Criteria: * Hepatocellular carcinoma or any other malignancy, * Child-Pugh grade C * Recent peptic ulcer disease * History of Hemorrhagic stroke * Pregnancy. * Uncontrolled Hypertension * Human immunodeficiency virus (HIV) infection
Contact & Investigator
Guo-Qing Jiang, MD
STUDY CHAIR
Clinical Medical College, Yangzhou University
Frequently Asked Questions
Who can join the NCT05338294 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cirrhosis, Liver. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05338294 currently recruiting?
Yes, NCT05338294 is actively recruiting participants. Contact the research team at jgqing2003@hotmail.com for enrollment information.
Where is the NCT05338294 trial being conducted?
This trial is being conducted at Yangzhou, China.
Who is sponsoring the NCT05338294 clinical trial?
NCT05338294 is sponsored by Northern Jiangsu People's Hospital. The principal investigator is Guo-Qing Jiang, MD at Clinical Medical College, Yangzhou University. The trial plans to enroll 20 participants.